Earlier, we showed that epidermal growth factor receptor (EGFR) signaling in human glioma cells increased cyclooxygenase-2 (COX-2) expression through p38-mitogen-activated protein kinase (MAPK)-dependent activation of the Sp family of transcription factors. Further mechanistic details of EGFR-dependent induction of COX-2 expression in glioma cells remained elusive. Protein kinase Cs (PKCs) comprise a family of serine-threonine kinases that are major mediators of signaling from receptor tyrosine kinases. Here, we report that PKC-d, a novel PKC isoform, plays a role in EGF-dependent COX-2 induction in human glioma cells. Pharmacological inhibition and genetic silencing (through siRNA or dominantnegative expression) of PKC-d confirm a role for this PKC isoform in EGF-dependent COX-2 induction. Overexpression of a functional PKC-d enhanced COX-2 expression indicating that PKC-d is not only necessary but also sufficient to regulate COX-2 levels. Inhibition of p38-MAPK pharmacologically or with siRNA further shows that p38-MAPK is required for activation of PKC-d by EGF while inhibition of PKC-d had no discernible effects on p38-MAPK activation. Finally, EGF stimulation promotes physical interactions between PKC-d and Sp1 resulting in phosphorylation and nuclear localization of this transcription factor. These data provide the first evidence that PKC-d is a critical link between p38-MAPK and Sp1-dependent COX-2 expression in human glioma cells.
Introduction
Malignant gliomas are the most common primary brain tumor in adults and patients with this diagnosis generally have poor outcomes. Increased expression and/or mutations of epidermal growth factor receptor (EGFR) are commonly seen in these tumors and contributes to their aggressive behavior (Libermann et al., 1985; Humphrey et al., 1991; Rosell et al., 2006) . EGFR signaling to downstream effectors such as phosphatidylinositol-3 kinase (PI-3K) and extracellular-related kinase 1/2 (ERK1/2) are likely responsible for mediating some of these effects. We recently found that EGFR-dependent activation of the p38-mitogen-activated protein kinase (MAPK) pathway can induce expression of cyclooxygenase-2 (COX-2), which we speculate, also enhances the malignancy of these astrocytic tumors. Less is known about other signaling molecules in this activation.
Protein kinase Cs (PKCs) comprise a family of phospholipid-dependent serine/threonine kinases that play important roles in various cellular responses, including cell survival, growth, differentiation, transformation and apoptosis (Musashi et al., 2000; Martelli et al., 2003; Hofmann, 2004) . The PKC family consists of at least 13 isoforms classified on the basis of structural differences that foster differing requirements for activation by diacylglycerol and calcium (Nishizuka, 1995; Newton, 1997) . These categories include classical PKCs (a, b1, b2 and g), novel PKCs (d, e, Z and y), atypical PKCs (z and i/l), and the recently described PKC-m and -n that do not fall into any of the aforementioned groups. EGFR can activate several members of this protein kinase family. Elevated PKC activity has also been reported in glioma cells as compared with normal astrocytes (Couldwell et al., 1991) . Although enhanced PKC activity correlates positively with the growth rate of malignant glioma cells, it remains unclear whether this association is causally related (Couldwell et al., 1990 (Couldwell et al., , 1991 Pollack et al., 1990; Baltuch and Yong, 1996; Bredel and Pollack, 1997) . Overall, upstream EGFR signals may contribute to excessive activation of PKCs in malignant gliomas leading to enhanced proliferation or other aggressive phenotypes associated with these tumors (Moriya and Tanaka, 1994; Baltuch and Yong, 1996; Bornancin and Parker, 1997) .
COX-2 plays important roles in tumor growth, metastasis, angiogenesis, and resistance to chemo-and radio-therapy (Shono et al., 2001; Karim et al., 2005; Bijnsdorp et al., 2007; Kang et al., 2007) and has been reported to be aberrantly overexpressed in human glioma (Joki et al., 2000; Prayson et al., 2002; Sminia et al., 2005; Buccoliero et al., 2006) . Moreover, increased COX-2 expression is an independent-negative prognostic factor in malignant gliomas (Shono et al., 2001) . Because PKC can regulate COX-2 expression in certain cell types by enhancing either transcription (through nuclear factor-kB and cAMP response element binding protein ) (Hsieh et al., 2007; Park et al., 2007) or stability of COX-2 mRNA (Doller et al., 2007) , we became interested in exploring whether PKCs would have similar effects on COX-2 expression in malignant glioma cells. Earlier we found that EGFR signaling induces COX-2 expression in glioma cells in a process requiring p38-MAPK and the activation of the Sp1 transcription factor (Xu and Shu, 2007) . Although EGFR activation can signal to several members of the PKC family, little is known about their role in regulation of COX-2 expression in human glioma cells. We now show that PKC-d is important for this process. This kinase is downstream of p38-MAPK in this EGFR-dependent signaling cascade and required for EGF-induced COX-2 expression in glioma cells. Furthermore, p38-MAPKdependent activation of PKC-d leads to direct interactions between PKC-d and Sp1 transcription factor. This results in phosphorylation of Sp1, promotion of Sp1 nuclear localization and transcriptional activation of COX-2.
Results

PKC-d inhibition impairs EGF-induced COX-2 expression
We have established earlier that EGF stimulation enhances COX-2 expression in multiple human glioma cells (Xu and Shu, 2007) . To explore the role of PKC in this EGF-induced process, two chemical inhibitors of PKCs, bisindolylmaleimide I (BIS) and chelerythrine chloride (Che) were used and found to significantly reduce EGF-induced expression of COX-2 protein in SF767 glioma cells (Figure 1a ). COX-2 mRNA was similarly affected with RNase protection assay showing impairment of EGF-induced COX-2 expression after general PKC inhibition with BIS ( Figure 1b) . We next assessed which member(s) of this kinase family is(are) required for EGFR-dependent COX-2 expression using the following PKC inhibitors: (1) GO6976 (GO, specific for classical PKCs), (2) rottlerin (Rott, specific for novel PKCs including PKC-d and -y) and (3) pseudosubstrate peptides targeting PKC-z (an atypical PKC). Of these inhibitors, only Rott suppressed induction of COX-2 in response to EGF stimulation (Figures 1a and c) . These results implicate the novel PKCs as a requirement for EGF-induced COX-2 induction in our glioma cells. Although the level of Rott (5 mM) used is reportedly specific for PKC-d, slight activity against PKC-y could not be completely excluded. Therefore, to determine whether PKC-y has a role in this process, we used a specific pseudosubstrate against the y isoform and found that EGF-induced COX-2 expression was unaffected ( Figure 1a) . Thus, PKC-d appears to be a necessary component of the signaling pathway(s) responsible for EGF-induced COX-2 expression. We further confirmed this finding in the LN229 glioma cell line thus showing that this result was not an effect unique to a single glioma cell line (data not shown). Because 'specific' small-molecule kinase inhibitors often display crossreactivity against 'nontargeted' kinases, we sought to confirm PKC-d's role in EGF-dependent COX-2 induction by selective genetic silencing of PKC-d. After introduction of a PKC-d-specific siRNA into SF767 cells, >90% reduction in PKC-d levels was seen by immunoblot analysis (Figure 1d , left panel). As expected, EGF-induced COX-2 expression was also significantly reduced ( Figure 1d, right panel) . Together, these results suggest that PKC-d is critical for EGFinduced COX-2 expression.
PKC-d is a downstream effector of p38-MAPK
Of the commonly assessed signaling effectors downstream of EGFR, p38-MAPK was consistently found to be the most significant regulator of EGF-induced COX-2 expression although ERK1/2 also had some modest regulatory effects ( (Xu and Shu, 2007) an unpublished data). In addition, although c-Jun N-terminal kinase (JNK) has not been specifically associated with EGFinduced COX-2 expression, this member of the MAPK family has been reported to regulate COX-2 expression in certain setting (Guan et al., 1998; Subbaramaiah et al., 1998) . Because PKC-d has been reported to regulate COX-2 expression by acting upstream of p38-MAPK and ERK1/2 in some systems (Hsieh et al., 2007; Park et al., 2007) , we pretreated SF767 cells with various PKC inhibitors, including BIS, Che, GO and Rott, prior to EGF stimulation and determined whether EGFinduced activation of p38-MAPK and ERK1/2 was affected. By immunoblot analysis, EGF-induced phosphorylation of p38-MAPK and ERK1/2 was unaffected by PKC inhibition, suggesting that they are not downstream targets of PKC-d in our system (Figure 2a , upper four panels). We also assessed JNK activation in this setting and found that it was similarly not affected by the pan-PKC inhibitors BIS and Che, although GO6976 and Rott did produce some mild off-targets effects on JNK activation (Figure 2a , lower two panels). We next speculated that MAPK signaling may be acting upstream of PKC-d. To test this hypothesis, we first confirmed that EGF-induced activation of PKC-d is detectable in SF767. Phosphorylation of PKC-d at threonine-505, a requirement for its activation, was detectable by immunoblotting with an antiphospho-PKC-d (P-PKC-d at Thr505) antibody. We found that EGF induces phosphorylation of PKC-d in a timedependent manner with peak levels seen by 10 min post-EGF stimulation ( Figure 2b ). Next, we assessed the effect of the p38-MAPK inhibitor SB202190 on EGFstimulated phosphorylation of PKC-d. Pretreatment with SB202190 not only reduced basal levels of PKC-d phosphorylation but also blocked EGF-stimulated phosphorylation of PKC-d (Figure 2c ), suggesting that PKC-d is a downstream target of p38-MAPK. Similar experiments with chemical inhibitors of MAP kinase/ERK kinase (MEK) and JNK did not alter the activation of PKC-d (data not shown). To further confirm that p38-MAPK acts upstream of PKC-d, p38-MAPK expression was silenced with a specific siRNA (which we had used earlier successfully (Xu and Shu, 2007) ) against this kinase in SF767. With this reagent, p38-MAPK was reduced to virtually undetectable levels ( Figure 2d , left panel) and, similar to our results with the p38-MAPK inhibitor, EGF was no longer able to stimulate phosphorylation of PKC-d, further corroborating p38-MAPK's role in EGF-dependent activation of PKC-d (Figure 2d , right panel).
Activation of p38-MAPK induces COX-2 expression in a process that requires PKC-d and the Sp family of transcription factors Although EGF-induced COX-2 expression clearly requires p38-MAPK, we sought to test whether the activation of p38-MAPK alone was sufficient to induce COX-2. MAPK kinase-3 (MKK3) and -6 (MKK6) are immediately upstream of p38-MAPK and their overexpression activates p38-MAPK by a means other than with EGF stimulation. Therefore, we separately transfected constitutively active forms of MKK3 and MKK6 into SF767 cells and found enhanced phosphorylation of p38-MAPK (P-p38) and, correspondingly, increased COX-2 expression in comparison to the vector-transfected control (Figure 3a) . Indeed, MKK3/6-induced 
PKC-d mediates EGF-stimulated transcription of COX-2
Thus far, our data indicate that PKC-d is a downstream mediator of p38-MAPK signaling to the Sp transcription factors. Therefore, as we have shown earlier that p38-MAPK-dependent COX-2 induction in glioma cells is predominantly through a transcriptional mechanism (Xu and Shu, 2007) , we postulated that pharmacological inhibition of PKC-d should also abolish EGF-induced COX-2 promoter activity. Various luciferase reporter constructs containing COX-2 promoter sequences were stably introduced into the SF767 glioma cells (Figure 5a ). After 5 h of EGF stimulation, we observed that luciferase activity was induced by 2.0-4.5-fold ( Figure 5b ). As predicted, this induction was completely blocked by pretreatment with the PKC-d inhibitor Rott (1 mm, GO) and rottlerin (5 mm, Rott) prior to stimulation with EGF (100 ng/ml) for 10 min. Blots were probed with antibodies against phosphorylated p38-MAPK (P-p38), p38-MAPK (p38), phosphorylated ERK1/2 (P-ERK1/2), ERK1/2, phosphorylated c-Jun N-terminal kinase (P-JNK), and JNK. (b) Cells were stimulated with EGF (100 ng/ml) for the indicated times. The blots were probed with antibodies against for phosphorylated PKC-d (Thr505, P-PKC-d) or PKC-d. (c) Cells were pretreated with SB202190 (10 mm, SB) for 1 h prior to stimulation with EGF (100 ng/ml) for the indicated times. Blots were probed with antibodies against P-PKC-d and PKC-d. (d) Cells were transfected as described in the Materials and methods section with control siRNA (C) or siRNA-targeting p38-MAPK (sip38). Forty-eight hours post-transfection, cells were treated with EGF (100 ng/ml) for 10 min and then harvested and lysed in SDS sample buffer. Immunoblotting was performed using antibodies against p38-MAPK, EIF5a (normalization control), P-PKC-d and PKC-d. In all cases, representative blots are shown from two to three independent experiments. SDS, sodium dodecyl sulfate; PKC, protein kinase C; EGF, epidermal growth factor; MAPK, p38-mitogen-activated protein kinase; ERK1/2, extracellular-related kinase 1/2. Figure 5b ). We also found that expression of WT-d in SF767 cells that contain the COX-2/P1 construct results in significant induction (1.5-2.0-fold) of luciferase activity ( Figure 5c ). The lower level of COX-2 promoter induction seen after transient introduction of these constructs compared with that seen after EGF stimulation can be explained by limited transient transfection efficiency in these cells (in the 50% range). Finally, to assess whether an intact Sp1 site is needed for PKC-ddependent promoter activation, WT-d was transiently introduced into SF767 cells containing the COX-2/P1m luciferase construct (mutated Sp1 site) (Figure 5a ). Again, as expected, no significant induction of luciferase activity was observed (Figure 5c ). These results further confirm that PKC-d activates the COX-2 gene promoter through the Sp1 site at À245 to À240 following EGF stimulation.
PKC-d is a mediator of Sp1 phosphorylation downstream of p38-MAPK
On the basis of our data above, we speculated that PKCd activity is required, in addition to p38-MAPK, for EGF-dependent Sp1 phosphorylation and that it may, in fact, be a direct Sp1 kinase. To assess this hypothesis, lysates derived from SF767 cells treated with EGF for 30 min with or without Rott were immunoprecipitated with an Sp1 antibody and further examined by immunoblot analysis with antibodies against phosphothreonine and Sp1. In this experiment, threonine phosphorylation of Sp1 was stimulated by EGF and could be blocked by PKC-d inhibition ( Figure 6a , left panel). In similar experiments, the Sp3 transcription factor was not found to be phosphorylated after EGF treatment (data not shown). These results were corroborated by the finding that forced expression , Bis (10 mm), Rott (5 mM) or Mith (100 nM) for 2 h prior to exposure to doxycycline (1 mg/ml) for 8 h. Cells were subsequently harvested and lysates evaluated by immunoblotting using antibodies against COX-2, EIF5a, P-p38 and p38. In all cases, representative blots are shown from two to three independent experiments. MAPK, p38-mitogen-activated protein kinase; PKC, protein kinase C; COX, cyclooxygenase-2.
EGF-dependent COX-2 induction requires PKC-d K Xu et al and the Sp1 transcription factor physically interacts in vivo in a process that is enhanced by EGF stimulation. To further confirm associations between PKC-d and Sp1, CAT-d and the vector-only control was transiently introduced into SF767 cells and lysates derived from these cells were subjected to immunoprecipitation using anti-HA-agarose affinity gel (CAT-d contains an hemagglutinin (HA) tag) and immunoblot analysis using antibodies against either Sp1 or PKC-d. Both CAT-d and Sp1 were detected in the complex pulled down by the anti-HA gel, again indicating a physical association between PKC-d and Sp1 (Figure 6c ). These data indicate that Sp1 physically interacts with and may be a direct kinase target of PKC-d.
p38-MAPK/PKC-d signaling promotes nuclear localization of Sp1
As Sp1 needs to localize to the nucleus to activate transcription of COX-2, we speculated that p38-MAPK/ PKC-d signaling may trigger Sp1 accumulation in the nucleus. When examining total cell lysates from SF767, Sp1 and Sp3 levels remained unchanged after EGF treatment (Figure 7a , left panel). However, when nuclear extracts were assessed, levels of Sp1 but not Sp3 increased following EGF treatment (Figure 7a , right panel). EGF-induced accumulation of Sp1 in the nucleus, but not the cytoplasm, was similarly seen in LN229 glioma cells with peaks reached between 30-60 min poststimulation (Figure 7b ). This Sp1 nuclear localization was blocked by both p38-MAPK and PKCd inhibition (Figure 7c ). These results indicate that nuclear localization of Sp1 is regulated by EGFdependent signaling through p38-MAPK/PKC-d and suggest that phosphorylation of Sp1 may be important for this process.
Discussion
We have shown earlier that the Sp1 transcription factor mediates increased activity of the COX-2 gene promoter in response to EGF-dependent p38-MAPK activation in glioma cells (Xu and Shu, 2007 ). In our current study, we now show that PKC-d is also required for EGF-and MKK3/6-induced COX-2 expression. We show mechanistically that PKC-d serves as a downstream target of p38-MAPK in this EGF-activated signaling pathway and its overexpression alone is sufficient to enhance expression of COX-2. Furthermore, PKC-d associates . In (b), the lower panels show results from cells either treated with or without doxycycline (1 mg/ml) with vehicle (V, dimethylsulfoxide only) or mith (100 ng/ml) for 48 h (in lower left panel) or transfected with control siRNA (C) or siRNA targeting Sp1 (siSp1) for 24 h prior to treatment with or without doxycycline (1 mg/ml) for 48 h (in lower right panel). Cells were subsequently harvested and lysates evaluated by immunoblotting using antibodies against COX-2, EIF5a and Sp1, as appropriate. In (c), the lower panels show results from cells treated with or without doxycycline (1 mg/ml) for 24 h prior to either addition of EGF (100 ng/ml) for 16 h (in lower left panel) or transient transfection with MKK3 (in lower right panel, harvested 40 h post-transfection). Cells were subsequently harvested and lysates evaluated by immunoblotting using antibodies against COX-2 and EIF5a. In all cases, representative blots are shown from two to three independent experiments. MKK3, MAPK kinase-3; PKC, protein kinase C; COX, cyclooxygenase-2; HA, hemagglutinin; EGF, epidermal growth factor.
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with and may directly phosphorylate the Sp1 transcription factor promoting its nuclear localization where it can act on the COX-2 promoter. Transcriptional regulation of COX-2 is not only relevant for malignant glioma cells. In fact, Sp1-dependent regulation of COX-2 has also been shown to be prominent in endothelial cells and cortical neurons Lee et al., 2006a) . These findings lead us to propose the existence of an EGFR/p38-MAPK/PKC-d signaling cascade that is important for Sp1 nuclear localization and the induction of COX-2 expression in glioma cells. Members of the PKC family of kinases are major mediators of growth factor signaling. Hepatocyte growth factor stimulation leads to translocation of PKC-a, -e and -g to the inner plasma membrane in neocortical cells thereby activating these isoforms (Machide et al., 1998) . Similarly, hepatocyte growth factor can activate PKC-a, -bII, -d and -z in a lung adenocarcinoma line (Awasthi and King, 2000) . Figure 5 EGF-dependent transcriptional activation of the COX-2 gene promoter requires PKC-d activity. SF767 cells were infected with retroviruses-containing luciferase driven by the COX-2 promoter regions as described in the Materials and methods section. (a) Schematics of the assessed COX-2 promoter-luciferase constructs are shown. The P1, P2 and P3 COX-2 promoter constructs consists of sequences from À1122, À828 and À670, respectively, to þ 27 relative to the transcriptional start site. The P1m construct is the P1 sequence whereby the Sp1 site at À245 to À240 is mutagenized to prevent binding of this transcription factor. (b) Graphs of luciferase activity from SF767 cells containing P1, P2 and P3. Cells were treated with rottlerin (rott, 5 mm) for 1 h and then stimulated with EGF (100 ng/ml) for 5 h. Relative luciferase activity with EGF ± Rott for each promoter construct was compared by a one-tailed unpaired student's t-test (* denotes a P-value o0.05 and ** denotes a P-value o0.01). Lysates from these transfectants were subjected to immunoprecipitation with anti-HA-agarose affinity gel to pull down exogenously expressed HA-PKC-d/CAT, when present. This was followed by immunoblotting using antibody against either Sp1 or PKC-d. In all cases above, representative blots from two independent experiments are shown. PKC, protein kinase C; EGF, epidermal growth factor.
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K Xu et al Lee et al. (2006b) found that EGF increases the translocation and activation of various PKC isoforms (PKC-a, -b1, -g, -d and -z), resulting in the activation of ERK1/2, p38-MAPK and JNK in chicken hepatocytes. Mimura et al. (2004) also reported that EGF induces fibronectin expression in human dermal fibroblasts through the PKC-d signaling pathway. Various PKC isoforms have been reported to regulate COX-2 expression (Wang et al., 2001; Pang et al., 2002; Yu et al., 2003) . However, the particular isoform(s) responsible for EGF-dependent COX-2 induction in glioma cells remained unclear. We now have multiple lines of evidence that PKC-d is critical for this process (EGFdependent COX-2 induction) in glioma cells. Although we have not widely examined whether this pathway for activation of COX-2 expression is seen in other systems, we did not find it active in the MCF-7 breast carcinoma and A431 epithelial carcinoma cell lines (unpublished data) suggesting that this may represent specific regulation in malignant gliomas.
Where PKC-d fit in EGF-dependent signaling cascade that leads to enhanced COX-2 expression in glioma cells has not been defined earlier. Iwabu et al. (2004) found that EGFR-dependent activation of phospholipase C-g contributes to PKC-d activation in mouse fibroblasts. PKC-d has also been reported to activate both p38-MAPK and ERK1/2 with Hsieh et al. (2007) finding that PKC-d regulates bradykinin-induced COX-2 expression through sequential activation of ERK1/2 and NF-kB in astrocytes and Park et al. (2007) reporting that acrolein-induced COX-2 expression requires the sequential activation of PKC-d, p38-MAPK and cAMP response element binding protein in human umbilical vein endothelial cells. These reports show that in certain cells, PKC-d can act upstream of p38-MAPK and ERK1/2 with subsequent induction of COX-2 expression. However, in our glioma cells, this is clearly not the case because suppression of PKC-d with either a general (BIS or Che) or a d-specific (Rott) inhibitor of PKC had no impact on EGF-induced activation of either p38-MAPK or ERK1/2 (Figure 2a) . We further found that inhibition of p38-MAPK with either SB202190 or a specific siRNA results in loss of EGF-dependent phosphorylation of PKC-d at Thr505 (Figures 2c-d) . Thus, p38-MAPK appears to mediate EGF-dependent activation of PKC-d, suggesting an EGFR/p38-MAPK/ PKC-d signaling cascade that regulates COX-2 transcription. To our knowledge, this is the first evidence that p38-MAPK is an upstream regulator of PKC-d. It is unclear why PKC-d is upstream of p38-MAPK in some cell types and downstream in others (such as our malignant glioma cells). However, it is not hard to speculate that such differences in signaling can increase the complexity of cellular responses potentially allowing better adaptation of a cell to its environment.
In our system, EGF-stimulated phosphorylation of Sp1 appears to require PKC-d activity. This Sp1 phosphorylation may control its ability to regulate gene expression. Others have shown that phosphorylation of Sp1 by ERK1/2, p38-MAPK and PKC-z stimulates its DNA-binding activity enhancing expression from promoters that contain Sp1-responsive elements. Zheng et al. (2001) showed that EGF stimulation of apoA-I expression is solely mediated by the Ras-Raf-MEK-ERK1/2 cascade and requires phosphorylation of Sp1 at Thr266. Similarly, Rojo et al. (2006) showed that regulation of the heme oxygenase-1 gene expression is through the PI-3K/PKC-z/ERK1/2 pathway that is crucial for the phosphorylation and function of Sp1. ERK-2-induced phosphorylation of Sp1 was also found to promote its binding to DNA and induce the gastrin gene promoter (Merchant et al., 1999; Chupreta et al., 2000) . Stress-mediated activation of p38-MAPK can also result in phosphorylation of Sp1 and induction of Sp1-dependent gene expression (D'Addario et al., 2002 (D'Addario et al., , 2006 . Finally, PKC-z has been implicated in the Sp1-dependent expression of vascular endothelial growth factor and PDGF-B through its ability to associate with and, potentially, directly phosphorylate Sp1 (Pal et al., 1998; Rafty and Khachigian, 2001; Reisinger et al., 2003) . On the basis of our data presented here, we now believe that PKC-d, as a downstream effector of p38-MAPK, regulates Sp1 function by driving its nuclear (Kuwahara et al., 2000) . One earlier defined phosphorylation site (Threonine-579) resides within this region, which we believe is a good candidate for regulating the nuclear localization of Sp1. The role of threonine-579 and/or other possible phosphorylation sites on the nuclear localization of Sp1 remain(s) to be defined. In summary, our study has elucidated an EGFR/p38-MAPK/PKC-d signaling cascade that drives nuclear localization of the Sp1 transcription factor leading to induction of COX-2 expression. We suggest that under conditions of excessive EGFR activity (commonly seen in malignant gliomas), COX-2 induction by this signaling cascade may contribute to malignant phenotypes seen in these aggressive brain tumors including tumor angiogenesis, increased proliferation and resistance to cytotoxic therapies. By precisely defining this signaling cascade, our studies not only identify a key pathway involved in the induction of COX-2 in glioma cells but also suggest specific targets for therapy with the goal being the development of novel therapeutic strategies against malignant glioma brain tumors.
Materials and methods
Plasmids
The wild-type COX-2 promoter DNA from bases À1122 to þ 27 (COX2/P1), À828 to þ 27 (COX2/P2) and -670 to þ 27 (COX2/P3) relative to the transcriptional start site and COX2/ P1 (À1122 to þ 27) with a mutant Sp1 site at À245 to À240 (COX2/P1m) were inserted upstream of the luciferase open reading frame in an MuLV-based retroviral vector as described earlier (Murphy et al., 2002; Xu and Shu, 2007) . MKK3be and MKK6be, constitutively active forms of these kinases, inserted in the mammalian expression vector pcDNA3 (Invitrogen, Carlsbad, CA, USA) were kindly provided by Dr Jiahuai Han (the Scripps Research Institute, La Jolla, CA, USA). WT-d; DN-d, with an inactivating point mutation in the kinase domain, and PKC-d/CAT (CAT-d), with truncation of the regulatory N-terminal domain protein but intact catalytic domain of PKC, in the mammalian expression vector pHACE which also adds a HA tag were kindly provided by Dr JaeWon Soh (Inha University, Incheon, Korea) (Soh et al., 1999) . WT-d and DN-d were excised from the pHACE vector with BamH1 and MKK3be was excised from pcDNA3 with EcoRI and each was inserted into pRetroX-Tight-Pur (Clontech, Mountain View, CA, USA).
Cell lines, culture conditions and transfections All cell lines (SF767, LN229, LN229/ER and Phoenix) were cultured in high glucose DME media (Sigma-Aldrich, St Louis, MO, USA) supplemented with 10% fetal calf serum (Sigma), Na pyruvate (1 mM) and penicillin (100 U/ml)/ streptomycin (100 mg/ml) unless otherwise indicated. LN229/ ER, engineered to overexpress wild-type EGFR has been described earlier (Li et al., 2004) . COX-2 promoter/luciferase constructs (pCOX2/P1, pCOX2/P2, pCOX2/P3, pCOX2/P1m) were stably introduced into SF767 for functional COX-2 promoter analysis. Each retroviral vector was transiently transfected into Phoenix cell by CaPO4 precipitation. SF767 cells were successively infected with conditioned supernatants from the transfected Phoenix cells and subsequently selected in the presence of 1 mg/ml G418 (Invitrogen). To transiently express constitutively active MKK3, MKK6 and the various PKC-ds, pcDNA3/MKK3be, pcDNA3/MKK6be and the pHACE/PKC-d constructs were transfected into SF767 cells using Lipofectamine 2000 (Invitrogen) according to manufacturer's recommendations. To generate cell lines with inducible expression of PKC-d and MKK3, pRetroX-Tet-On Advanced (Clontech) and the pRetroX-Tight-Pur vector-containing WTd and DN-d were sequentially introduced/infected into SF767, similar to the procedure described above, and selected in the presence of 1 mg/ml G418 and 2 mg/ml puromycin to obtain the SF767/tet/WT-d and SF767/tet/DN-d cell lines. Doxycycline (1 mg/ml) was used to induce expression of the gene of interest. For siRNA suppression, SF767 cells were transfected with commercially available siRNA against PKC-d, p38-MAPK and Sp1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) using Lipofectamine 2000 or FuGENE 6 (Roche Diagnostics, Indianapolis, IN, USA). The Stealth RNAi medium GC duplex-negative control (Invitrogen) was used to control for sequence-independent effects of introducing short RNA duplexes into cells.
Growth factor and inhibitor treatments
Cells were serum starved for 24 h prior to ligand stimulation with EGF (100 ng/ml, Roche), except as otherwise noted. dimethylsulfoxide stock solutions of inhibitors against the following kinases p38-MAPK (SB202190, Calbiochem, San Diego, CA, USA), all PKC isoforms (BIS and Che, Calbiochem), classic PKCs (GO6976, Calbiochem) and PKCd (Rott, Calbiochem) were made. Inhibitors (psuedosubstrate peptides) against PKC-y and -z (Calbiochem) were made as stock solutions in water. Working concentrations for each particular inhibitor are noted in the figure legends with vehicleonly (dimethylsulfoxide) used as a negative control, when appropriate. Mithramycin A (Sigma), an inhibitor of the Sp family of transcription factors, was also made as a stock solution in dimethylsulfoxide and used as noted in the text.
Preparation of subcellular extracts and immunoprecipitation
Nuclear and cytoplasmic extracts were prepared as follows: cells were pelleted, resuspended in 900 ml of ice-cold EBKL buffer (25 mM HEPES, pH7.6, 5 mM MgCl 2 , 1.5 mM KCl, 2 mM dithiothreitol, 0.1% NP-40 and protease inhibitor cocktail (Sigma)) and lysed on ice with Dounce homogenization. Nuclei were then pelleted at 1000 g Â 5 min. Supernatant was designated as cytoplasmic extract. Pelleted nuclei were then washed in EBMK buffer (25 mM HEPES, pH7.6, 5 mM MgCl 2 , 1.5 mM KCl, 75 mM NaCl, 175 mM sucrose, 2 mM dithiothreitol and protease inhibitor cocktail), spun (600 g Â 5 min) and washed with EBMK þ 0.5% NP-40. Nuclei were again pelleted and resuspended in EBKL (100 ml), incubated on ice Â 10 min and lysed by increasing KCl concentration to 0.2 M (with 5 M KCl stock), followed by sonication to shear genomic DNA. This was designated as the nuclear extract. For immunoprecipitation, whole-cell lysates were precleared with protein A agarose beads (Roche) and then incubated with protein A beads prebound to specific antibodies at 4 1C overnight. Beads were subsequently washed three times with lysis buffer, resuspended in 50 ml sodium dodecyl sulfate sample buffer and heated to 95 1C for 5 min to EGF-dependent COX-2 induction requires PKC-d K Xu et al release the immunoprecipitated protein. For HA-tagged PKCd/CAT, immunoprecipitation was performed using anti-HAagarose affinity gel (Sigma) and bound HA-tagged PKC-d/ CAT or Sp1 was eluted by the lysis buffer containing HA peptide (100 mg/100 ml, Sigma).
Immunoblotting and antibodies used
Immunoblots were performed according to standard procedures. Total cell lysates were prepared with an sodium dodecyl sulfate lysis buffer (62.5 mM Tris-Cl, pH6.8, 2% sodium dodecyl sulfate, 10% glycerol, 50 mM dithiothreitol, 0.01% bromophenol blue) and sonication to shear genomic DNA.
Lysates were resolved by SDS-polyacrylamide gel electrophoresis and electrotransferred to PVDF. Blots were probed with antibodies against human PKC-d (Santa Cruz Biotechnology), phosphorylated PKC-d (phospho-Thr505, Cell Signaling Technology, Beverly, MA, USA), COX-2 (Cayman Chemical, Ann Arbor, MI, USA), p38-MAPK/phosphorylated p38-MAPK (phospho-Thr180/Tyr182) (Cell Signaling Technology), Sp1/Sp3 (Santa Cruz), hemagglutinin (Sigma) and phosphothreonine (Cell Signaling Technology). Antibodies against EIF5a, tubulin or histone (Santa Cruz) were used as normalization controls, where appropriate. Detection of blots was accomplished by using either anti-rabbit or mouse IgG secondary antibody conjugated with horseradish peroxidase and chemiluminescent substrate (Pierce, Rockford, IL, USA).
RNase protection assay
RNase protection assay was performed by standard techniques as described earlier (Xu and Murphy, 2000) . Briefly, 5 mg of total RNA was incubated with the 32 P-labeled riboprobe of interest in 10 ml hybridization buffer (40 mM HEPES, pH 6.4, 300 mM NaCl, 80% formamide, 1 mM ethylenediaminetetraacetic acid) overnight at 42 1C and then digested with RNase A/T 1 . Protected riboprobes were EtOH precipitated, resolved with a 5% urea/polyacrylamide gel, and detected by phosphor imaging on a Typhoon 9210 system using ImageQuant software (Molecular Dynamics, GE Healthcare, Piscataway, NJ, USA).
Luciferase reporter assay
Luciferase reporter assays were performed using pooled cells as described earlier (Xu and Shu, 2007) . Briefly, the human COX-2 promoter/luciferase reporter constructs were stable, introduced by retroviral transduction. With EGF treatment, B80% confluent cells were cultured in serum-free medium overnight in 24-well plates prior to addition of EGF Â 5 h. With transient introduction of the PKC-d constructs, cells were serum starved for 24 h following transfection. Luciferase activity was measured as described earlier (Abbott et al., 2000; Xu and Shu, 2007) .
